Foresight Diagnostics, a privately held cancer diagnostics company, has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems, resolving ongoing litigation between the parties. As part of the resolution, all claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.

Under the agreement, Foresight has granted Roche a limited, royalty-bearing, non-exclusive sublicense to use its patented PhasED-Seq technology for the development of in vitro diagnostic (IVD) kits targeting non-Hodgkin’s lymphoma (NHL). Importantly, the intellectual property rights to PhasED-Seq remain with Stanford University, while Foresight retains exclusive rights to the patents across all other uses and geographies.

Jake Chabon, PhD, chief executive officer of Foresight Diagnostics, said, “We are pleased to have resolved our differences with Roche and to move forward with this licensing agreement, which provides Roche with tailored rights in the field of non-Hodgkin’s lymphoma. This resolution allows Foresight to remain focused on our mission to advance cutting-edge diagnostics aimed at improving outcomes for cancer patients worldwide.”

The Phased Variant Enrichment and Detection by Sequencing (PhasED-Seq) technology underpins the Foresight MRD platform. It enhances mutation detection accuracy by requiring the concordant identification of two separate non-reference events in a single DNA molecule, enabling highly sensitive detection of circulating tumour DNA (ctDNA) at levels below one part-per-million. PhasED-Seq has been validated in thousands of patient samples and is a core component of Foresight CLARITY, the company’s novel liquid biopsy assay designed to measure minimal residual disease (MRD).

Foresight Diagnostics, headquartered in the United States, operates as a CLIA-registered laboratory and continues to develop advanced diagnostics to support cancer care worldwide.